A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

AIDS

Volumn 17, Issue 17, 2003, Pages 2487-2494

  Gruzdev, Boris ^a   Rakhmanova, Aza ^b   Doubovskaya, Ekaterina ^a   Yakovlev, Alexey ^b   Peeters, Monika ^c   Rinehart, Alex ^d   De Dier, Karin ^c   Baede Van Dijk, Patricia ^e   Parys, Wim ^d   Van't Klooster, Gerben ^c,f  

^a Infectious Diseases Hospital   (Russian Federation)

^b NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^c Virco BVBA   (Belgium)

^d Tibotec   (United States)

^e Kinesis   (Netherlands)

^f TIBOTEC BVBA   (Belgium)

Author keywords

Clinical trials; HIV drug resistance resistance mutations; Monotherapy; Non nucleoside reverse transcriptase inhibitor; Pharmacokinetics; TMC125

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; ETRAVIRINE; PLACEBO; URIC ACID;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEVER; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SKIN DISEASE; SOMNOLENCE; STEADY STATE; TACHYCARDIA; TONSILLITIS; VIRUS LOAD; VOMITING;

ADULT; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 12144289848     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200311210-00011     Document Type: Article

References (21)

1. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
2. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
3. Richman D, Bozzette S, Morton S, Chien S, Wrin T, Dawson K, et al. The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antiviral Agents and Chemotherapy. Chicago, December 2001 [abstract LB-17].
4. Rousseau MN, Vergne L, Montes B, Peeters, J. Reynes, E. Delaporte, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 26:36-43.
5. Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HJ, Jr, Powderly WC, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001, 32:124-129.
6. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:426-431.
7. Welch KJ, Morse A. Association between efavirenz and selected psychiatric and neurological conditions. J Infect Dis 2002, 185:268-269.
8. de Bethune MP, Hertogs K, Azijn H, Larder B, Andries K, Janssen PAJ, et al. R165335-TMC125, a third generation non nucleoside reverse transcriptase inhibitor (NNRTI), inhibits 98% of more than 2000 recombinant HIV clinical isolates at 100 nM. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [abstract 1841].
9. Piscitelli S, Baede P, DeDier K, Van't Klooster C, Graham N. Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers. Third International Workshop on Clinical Pharmacology of HIV Therapy. Washington DC, April 2002 [abstract 5.3].
10. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transciptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
11. Division of AIDS. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institutes of Allergy and Infectious Diseases; 1996.
12. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001, 15:1671-1677.
13. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44:2475-2484.
14. Louie M, Ramratnam B, Kost R, Hurley A, Zhang L, Sun E, et al. Using viral dynamics to document the greater antiviral potency of a regimen containing lopinavir/ritonavir, efavirenz, tenofovir, and lamivudine relative to standard HAART. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 383].
15. Mittler J, Essunger P, Yuen CJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001, 45:1438-1443.
16. Weverling CJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998, 12:F117-F122.
17. Sankatsing SUC, Weverling GJ, Peeters M, Van't Klooster C, Gruzdev B, Rakhmanova A, et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003 (in press).
18. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999, 13:1873-1880.
19. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989, 84: 1056-1062.
20. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001, 15: 1951-1957.
21. Bacheler L, Jeffrey S, Hanna C, D'Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001, 75:4999-5008.